公开(公告)号：EP1315831A2

公开(公告)日：2003-06-04

申请号：EP01920143.3

申请日：2001-02-23

申请人： Xenon Genetics Inc. ,  WISCONSIN ALUMNI RESEARCH FOUNDATION ,  University of British Columbia

发明人： BROWNLIE, Alison, J. ,  HAYDEN, Michael, R. ,  ATTIE, Alan, D. ,  NTAMBI, James, M. ,  GRAY-KELLER, Mark, P. ,  MIYAZAKI, Makoto

IPC分类号： C12Q1/26

CPC分类号： C12N15/1137 ,  A61K31/00 ,  A61K31/201 ,  A61K31/426 ,  A61K31/4439 ,  A61K48/00 ,  C07K16/40 ,  C12N9/0083 ,  C12Q1/26 ,  G01N2333/90245 ,  Y10S514/866 ,  Y10S514/909

摘要： The use of screening assays based on the role of human stearoyl-CoA desaturase-1 ('hSCD1') in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids., wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.

公开(公告)号：EP1315831B1

公开(公告)日：2010-07-28

申请号：EP01920143.3

申请日：2001-02-23

申请人： Xenon Pharmaceuticals Inc. ,  WISCONSIN ALUMNI RESEARCH FOUNDATION ,  UNIVERSITY OF BRITISH COLUMBIA

发明人： BROWNLIE, Alison, J. ,  HAYDEN, Michael, R. ,  ATTIE, Alan, D. ,  NTAMBI, James, M. ,  GRAY-KELLER, Mark, P. ,  MIYAZAKI, Makoto

IPC分类号： C12Q1/26

CPC分类号： C12N15/1137 ,  A61K31/00 ,  A61K31/201 ,  A61K31/426 ,  A61K31/4439 ,  A61K48/00 ,  C07K16/40 ,  C12N9/0083 ,  C12Q1/26 ,  G01N2333/90245 ,  Y10S514/866 ,  Y10S514/909

摘要： The use of screening assays based on the role of human stearoyl-CoA desaturase-1 ('hSCD1') in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids., wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.

摘要翻译： 基于人硬脂酰辅酶A去饱和酶-1（'hSCD1'）在与甘油三酯，VLDL，HDL，LDL，总胆固醇或血清中的分泌物产生相关的人类疾病，病症或病症中的作用的筛选测定的用途 粘膜，单不饱和脂肪酸，蜡酯等。 还公开了用于预防和/或治疗这些疾病的惯例。

公开(公告)号：EP1315831B8

公开(公告)日：2010-09-01

申请号：EP01920143.3

申请日：2001-02-23

申请人： Xenon Pharmaceuticals Inc. ,  Wisconsin Alumni Research Foundation

发明人： BROWNLIE, Alison, J. ,  HAYDEN, Michael, R. ,  ATTIE, Alan, D. ,  NTAMBI, James, M. ,  GRAY-KELLER, Mark, P. ,  MIYAZAKI, Makoto

IPC分类号： C12Q1/26

CPC分类号： C12N15/1137 ,  A61K31/00 ,  A61K31/201 ,  A61K31/426 ,  A61K31/4439 ,  A61K48/00 ,  C07K16/40 ,  C12N9/0083 ,  C12Q1/26 ,  G01N2333/90245 ,  Y10S514/866 ,  Y10S514/909

公开(公告)号：EP1227818A2

公开(公告)日：2002-08-07

申请号：EP00976795.5

申请日：2000-11-01

申请人： WISCONSIN ALUMNI RESEARCH FOUNDATION

发明人： ATTIE, Alan, D. ,  COOK, Mark ,  GRAY-KELLER, Mark, P. ,  HAYDEN, Michael, R. ,  PIMSTONE, Simon ,  BROOKS-WILSON, Angie

IPC分类号： A61K31/64

CPC分类号： C12Q1/6883 ,  A61K31/64 ,  A61K49/0008 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5008 ,  G01N33/566 ,  G01N33/92 ,  G01N2500/00 ,  G01N2500/04 ,  G01N2800/044

摘要： Methods and compounds are disclosed for lowering serum LDL levels or serum cholesterol levels, or for reducing the transport of cholesterol from the gut to the blood or the lymph, based on the observation that a gene known as ABC1 is necessary in order for cholesterol to be transported from the intestinal lumen into the bloodstream. A mutant chicken phenotype, known as the WHAM chicken, characterized by low levels of serum LDL and reduced transport of cholesterol, facilitated the discovery of this function of the ABC1 gene. Techniques which act to inhibit ABC1 activity in the cells of the intestinal wall will result in lower serum cholesterol.

公开(公告)号：EP1429784A2

公开(公告)日：2004-06-23

申请号：EP02759524.8

申请日：2002-08-29

申请人： Xenon Genetics, Inc.

发明人： WINTHER, Michael, D. ,  GRAY-KELLER, Mark, P.

IPC分类号： A61K31/675 ,  A61K47/00 ,  A01N25/00 ,  C12N15/09 ,  C12P21/06 ,  C12Q1/26

CPC分类号： C12Q1/26 ,  C12Q1/48 ,  G01N33/60 ,  G01N2333/90245 ,  G01N2333/91051 ,  G01N2500/04

摘要： High throughput screening assays for the identification of potential therapeutic agents able to modulate the activity of enzymes of fatty acid biosynthesis, especially desaturases and/or elongases, are disclosed along with therapeutic uses of the agents identified by such assays for the prevention and/or treatment of diseases related to fatty acid metabolism. Substrates useful in such assays are also described.